International Comparison of ADHD Clinical Practice Guidelines: Comparing NICE, UMHS, and CADDRA Guidelines to Consider the Latest ADHD Practice

Sugimoto, Atsunori; Someya, Toshiyuki

doi:10.1007/978-3-030-62059-2_403

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In almost all Asian countries, barring Japan, MPH is the mainstay pharmacological treatment for ADHD. Although the approval status and guidelines recommend MPH and ATX as the first‐line pharmacologic treatment in many European countries, the Canadian ADHD Resource Alliance (CADDRA), and NICE guidelines recommend ATX and GXR as second‐line treatment 4,21,22 . Pharmacological treatment trends in Asian countries and regions may be based on these highly evaluated clinical practice guidelines.…”

Section: Discussionmentioning

confidence: 99%

“…Although the approval status and guidelines recommend MPH and ATX as the first‐line pharmacologic treatment in many European countries, the Canadian ADHD Resource Alliance (CADDRA), and NICE guidelines recommend ATX and GXR as second‐line treatment. 4 , 21 , 22 Pharmacological treatment trends in Asian countries and regions may be based on these highly evaluated clinical practice guidelines. The prevalence of ADHD in school‐aged children varies considerably between countries; for example, white individuals have higher rates of ADHD than Asian individuals.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia

Kawabe,

Horiuchi,

Matsumoto

et al. 2023

Neuropsychopharm Rep

View full text Add to dashboard Cite

Attention‐deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)‐approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first‐line treatment, with pharmacological treatment added as the second‐line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia

Kawabe,

Horiuchi,

Matsumoto

et al. 2023

Neuropsychopharm Rep

View full text Add to dashboard Cite

show abstract

Lignes directrices pour l’examen diagnostique des troubles neurodéveloppementaux chez l'adulte en neuropsychologie

Candal-Zürcher,

Chatelain,

Verdon,

2022

NCACN

View full text Add to dashboard Cite

Les demandes d’évaluation neuropsychologique pour les troubles neurodéveloppementaux chez l’adulte augmentent significativement. Bien que ce sujet ait donné lieu à de nombreuses recherches chez les enfants, ce thème reste relativement inexploré chez les adultes et les études décrivant la symptomatologie, son évolution et son impact fonctionnel demeurent rares. De plus, le diagnostic chez l’adulte connaît plusieurs défis liés notamment au chevauchement de symptomatologies ou à la présence de comorbidités. Cet article propose une revue de la littérature de deux entités, le Trouble du Déficit de l’Attention/Hyperactivité et le Trouble du Spectre de l’Autisme, avec quelques considérations autour de la problématique du haut potentiel. Sur la base d’études récentes et de recommandations de sociétés savantes, l’objectif est de proposer des lignes directrices afin de guider l’évaluation neuropsychologique. Le but est d’améliorer l’harmonisation des pratiques grâce à une démarche basée sur les preuves afin de proposer une prise en charge optimale au patient. Nowadays, the number of neuropsychological evaluation requests concerning neurodevelopmental disorders in adults is expending. While the litterature has grown significantly over the past decades regarding this topic in children, we still lack of studies in adultes that would adress the symptomatology, its course and its functional impairments. Moreover, symptomatologies overlap, comorbidties or social gratification are ones of the many challenges when diagnosing adults. This paper is an attempt to review the recent litterature concerning two specific neurodevelopmental disorders, namely Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), to which we added some considerations about the gifted profile in adults. Based on the latest researches and recommendations from experts, we aimed to propose guidelines for the clinician meant to ease the management of the evaluation process. We hope this work could lead to standardization of evidence-based practices that would eventually benefit the patient.

show abstract

International Comparison of ADHD Clinical Practice Guidelines: Comparing NICE, UMHS, and CADDRA Guidelines to Consider the Latest ADHD Practice

Cited by 2 publications

References 9 publications

Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia

Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia

Lignes directrices pour l’examen diagnostique des troubles neurodéveloppementaux chez l'adulte en neuropsychologie

Contact Info

Product

Resources

About